| __timestamp | Bristol-Myers Squibb Company | Summit Therapeutics Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 6795238 |
| Thursday, January 1, 2015 | 5001000000 | 7454247 |
| Friday, January 1, 2016 | 5002000000 | 10345862 |
| Sunday, January 1, 2017 | 4849000000 | 16984203 |
| Monday, January 1, 2018 | 4551000000 | 16187290 |
| Tuesday, January 1, 2019 | 4871000000 | 9299233.54 |
| Wednesday, January 1, 2020 | 7661000000 | 19232000 |
| Friday, January 1, 2021 | 7690000000 | 23611000 |
| Saturday, January 1, 2022 | 7814000000 | 26700000 |
| Sunday, January 1, 2023 | 7772000000 | 28215000 |
| Monday, January 1, 2024 | 8414000000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, Bristol-Myers Squibb Company (BMY) and Summit Therapeutics Inc. (SMMT) have shown contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, BMY's SG&A expenses surged by approximately 36%, peaking in 2022 with a notable 7.8 billion dollars. This reflects their aggressive expansion and strategic investments. In contrast, Summit Therapeutics, a smaller player, saw its SG&A expenses grow by over 300%, reaching nearly 28 million dollars in 2023. This sharp increase highlights their efforts to scale operations and enhance market presence. These trends underscore the differing strategies of a pharmaceutical giant versus a nimble biotech firm, offering insights into their operational priorities and market dynamics.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Summit Therapeutics Inc.
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Summit Therapeutics Inc.
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Summit Therapeutics Inc.
Neurocrine Biosciences, Inc. and Summit Therapeutics Inc.: SG&A Spending Patterns Compared
Intra-Cellular Therapies, Inc. vs Summit Therapeutics Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Summit Therapeutics Inc. vs Merus N.V. Trends and Insights